In a stage I clinical trial, DCs were transduced with an adenoviral (Ad) vector expressing the CCL21 gene (Ad-CCL21-DC), which induced systemic tumor antigen-specific immune responses, enhanced tumor CD8+ T cell infiltration, and increased tumor PDL1 expression [123]. Here, CCL21 is linked to neoplasm.